Search

Displaying results 6061 - 6070 of 10000 in total
  1. Drug

    Mitiglinide

    go.drugbank.com/drugs/DB01252
    Investigational

    It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

    Categories: Alimentary Tract and Metabolism
  2. Drug

    Nitroarginine

    go.drugbank.com/drugs/DB04223
    Investigational

    Nitroarginine has been experimentally tested for its ability to prevent ammonia toxicity and ammonia-induced alterations in brain energy and ammonia metabolites. (Neurochem Res 1995:200(4):451-6) … An inhibitor of nitric oxide synthetase which has been shown to prevent glutamate toxicity.

    Categories: Amino Acids, Peptides, and Proteins
  3. Drug

    ALT-2074

    go.drugbank.com/drugs/DB05631
    Investigational

    An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated.

  4. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  5. Drug

    Solabegron

    go.drugbank.com/drugs/DB06190
    Investigational

    Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

    Categories: Drugs for Urinary Frequency and Incontinence
  6. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  7. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is developed for the treatment of Parkinson’s disease and psychoses, including bipolar disorder, for which disease existing therapies have only limited effect and considerable adverse side effects … ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.

  8. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    an altered sensitivity to IgE conformation. … While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the

    Categories: Amino Acids, Peptides, and Proteins
  9. Indication

    Invasive Meningococcal Disease caused by Neisseria meningitidis serogroup C

    go.drugbank.com/conditions/DBCOND0093726
    Drugs: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine · Meningococcal polysaccharide vaccine group C · Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen · Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen · Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen
  10. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes. … It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241]